Johnson & Johnson (NYSE:JNJ) has lost a court battle over its drug-coated stent patents after a New Jersey federal judge ruled that stents marketed by Boston Scientific (NYSE:BSX) Abbott Laboratories (NYSE:ABT) and Medtronic (NYSE:MDT) had not infringed stent patents held by the New Brunswick, New Jersey company.
Despite the ruling, a Johnson & Johnson spokeswoman said in an email that the company would appeal the decision.
Johnson & Johnson ended its drug-coated stent business last year and exited a lucrative $4 billion market amidst setbacks in its business that included manufacturing problems, unfavorable patent decisions and greater competition.
In 2010, Boston Scientific agreed to pay J&J $1.73 billion to end other patent lawsuits between the companies over stent technology.
By Stephanie Baum
Stephanie Baum is the East Coast Innovation Reporter for MedCityNews.com. She enjoys covering healthcare startups across health IT, drug development and medical devices and innovations deployed to improve medical care. She graduated from Franklin & Marshall College in Pennsylvania and has worked across radio, print and video. She's written for The Christian Science Monitor, Dow Jones & Co. and United Business Media.Visit website | More posts by Author
- Get Livefyre
- FAQ
